Quarterly report · Q2
4361.TEDINET S100TZZY
Period2023-12-01 → 2024-05-31
Filed2024-07-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.2bn | 2023-12-01 → 2024-05-31 | Cons. | Net sales |
| Revenue | ¥8.6bn | 2022-12-01 → 2023-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.2bn | 2022-12-01 → 2023-05-31 | Cons. | Net sales |
| Operating income | ¥202m | 2023-12-01 → 2024-05-31 | Cons. | Operating income |
| Operating income | ¥156m | 2022-12-01 → 2023-05-31 | Cons. | Operating income |
| Ordinary income | ¥212m | 2023-12-01 → 2024-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥345m | 2022-12-01 → 2023-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥156m | 2022-12-01 → 2023-05-31 | Cons. | Ordinary income |
| Profit before tax | ¥252m | 2023-12-01 → 2024-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥155m | 2022-12-01 → 2023-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥193m | 2023-12-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥256m | 2022-12-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥121m | 2022-12-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥193m | 2023-12-01 → 2024-05-31 | Cons. | Profit loss |
| Net income | ¥121m | 2022-12-01 → 2023-05-31 | Cons. | Profit loss |
| Total assets | ¥8.0bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥8.0bn | at 2023-05-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.3bn | at 2024-05-31 | Cons. | Liabilities |
| Total liabilities | ¥5.7bn | at 2023-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥2.7bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥2.6bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.5bn | at 2023-05-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥947m | at 2024-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥947m | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥999m | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥911m | at 2022-11-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥90m | 2023-12-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥470m | 2022-12-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥223m | 2022-12-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥96m | 2023-12-01 → 2024-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥370m | 2022-12-01 → 2023-11-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥217m | 2022-12-01 → 2023-05-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥101m | 2023-12-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥21m | 2022-12-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥80m | 2022-12-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥158.38 | 2023-12-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥117.59 | 2024-03-01 → 2024-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.88 | 2022-12-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.17 | 2022-12-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.39 | 2023-03-01 → 2023-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 34.2% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.1% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2023-12-01 → 2024-05-31 | ¥4.2bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2023-12-01 → 2024-05-31 | ¥4.2bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2023-12-01 → 2024-05-31 | ¥187m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue | 2023-12-01 → 2024-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue external | 2023-12-01 → 2024-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | segment profit | 2023-12-01 → 2024-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-12-01 → 2024-05-31 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-12-01 → 2024-05-31 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-12-01 → 2024-05-31 | ¥202m |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2022-12-01 → 2023-05-31 | ¥4.2bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2022-12-01 → 2023-05-31 | ¥4.2bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2022-12-01 → 2023-05-31 | ¥141m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue | 2022-12-01 → 2023-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue external | 2022-12-01 → 2023-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | segment profit | 2022-12-01 → 2023-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-12-01 → 2023-05-31 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-12-01 → 2023-05-31 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-12-01 → 2023-05-31 | ¥156m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 480
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | － | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 370000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -50796000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -401668000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -8861000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -8861000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -60513000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -60433000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 79828000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -100963000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 2411000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 10749000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 88421000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -96838000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 910919000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1043816000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 999341000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 946977000 | JPY |
| Employee payrolls and allowances sga | Prior1YTDDuration | 143080000 | JPY |
| Employee payrolls and allowances sga | CurrentYTDDuration | 143944000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 21333000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 7328000 | JPY |
| Provision for directors bonuses sga | Prior1YTDDuration | 5400000 | JPY |
| Provision for directors bonuses sga | CurrentYTDDuration | 5700000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 5400000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 5118000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 112952000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 120269000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4187724000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 19179000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 4206904000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 4206904000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4187724000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 19179000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 4206904000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 4206904000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 140979000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 15375000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 156355000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 156355000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4229080000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 19197000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |